RxDoctor Payments Data

Joe Griffin, MD

Internal Medicine · Savannah, GANPI 1831198696

Payments from drug & device makers

$1,065in general payments, 2019–2025

Across 65 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$281
  • Novo Nordisk$189
  • Novartis$162
  • AbbVie$96
  • Pfizer$91
  • Amarin Pharma, Inc.$34
  • plus $212 from 12 others

What the payments were for

  • Food & beverage$1,065100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,065 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$155,820
Medicare patients
249
Services billed
10,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$147,845
EliquisApixaban134$136,331
JardianceEmpagliflozin77$74,367
JanuviaSitagliptin Phosphate46$50,524
FarxigaDapagliflozin Propanediol37$27,936
TrulicityDulaglutide19$23,763
MyrbetriqMirabegron28$19,493
EntrestoSacubitril/Valsartan18$19,405
JanumetSitagliptin Phos/Metformin Hcl11$18,178
MounjaroTirzepatide16$16,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,232
Combivent RespimatIpratropium/Albuterol Sulfate19$16,222
Tresiba Flextouch U-200Insulin Degludec29$15,361
XareltoRivaroxaban13$14,611
GemtesaVibegron11$10,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$189$147,845102 claims
PfizerEliquis, Paxlovid$91$139,128176 claims
MerckJanuvia, Janumet$11$68,70357 claims
Lilly USA, LLCTrulicity, Mounjaro$14$40,00835 claims
AstraZenecaFarxiga$30$27,93637 claims
NovartisEntresto$162$19,40518 claims
AbbVieSynthroid$96$4,05046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →